Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Breast Cancer Res Treat. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
PMCID: PMC2949487

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers


Risk-reducing salpingo-oophorectomy (RRSO) is widely used for cancer risk reduction in BRCA1 or BRCA2 (BRCA1/2) mutation carriers. Occult ovarian/fallopian tube cancers (OOC) detected at the time of RRSO have been reported in several studies with wide variability in reported prevalence. We estimated the prevalence of OOC in a prospective cohort of 647 BRCA1/2 mutation carriers from 18 centers (PROSE consortium) who under-went RRSO between 2001 and 2008. OOC was detected in 16 of 647 women (2.5%). The mean age at RRSO was 51.7 in those with OOC versus 46.6 in those without OOC (P = 0.017). Twelve of the 16 OOCs (75%) were diagnosed in women with BRCA1 mutations. Thirty-eight percent of women with OOC had stage 1 cancer versus none of the women in the PROSE database diagnosed with ovarian cancer outside of screening. Among 385 women (60%) in whom pathology reports were available for central review, 246 (64%) RRSOs were performed at participating PROSE centers while 139 (36%) were performed at local sites. Ovarian and fallopian tube tissues removed at major genetics referral centers were significantly more likely to have been examined in toto compared to specimens obtained at non-referral centers (75% vs. 30%, P < 0.001). Our results confirm that OOC may be found at the time of RRSO in BRCA1/2 mutation carriers and suggest that OOC are of a more favorable stage than cancers found outside RRSO. An unacceptably high proportion of pathologic examinations did not adequately examine ovaries and fallopian tubes obtained at RRSO.

Keywords: Hereditary ovarian cancer, Prophylactic Surgery, BRCA1, BRCA2


Women with inherited BRCA1 or BRCA2 (BRCA1/2) mutations are recommended to undergo risk-reducing salpingo-oophorectomy bilateral prophylactic oophorectomy(RRSO) to reduce their cancer risk, generally by age 40 or after the completion of childbearing [1, 2]. In BRCA1/2 mutation carriers, RRSO reduces the risk of ovarian cancer by approximately 85–90% and the risk of breast cancer by 50% or more [3], and may also impact cancer-specific and overall mortality [4]. These numbers also reflect the fact that cancer risk reduction associated with RRSO is not complete, and that residual risk may exist for peritoneal cancers even after RRSO. Furthermore, women who undergo RRSO undergo premature menopause, which may confer risk for complications such as hot flashes, osteopenia, and heart disease [5]. While there is some evidence that short-term use of hormone replacement therapy after RRSO does not negate the reduction in breast cancer risk conferred by RRSO [6, 7] careful consideration of the timing and risks versus benefits of RRSO need to be considered prior to surgery in women with BRCA1/2 mutations who are deciding on their options for cancer prevention.

Occult ovarian and fallopian tube cancers (OOC) have been reported at the time of RRSO (reviewed in [8]). The prevalence of OOC has been estimated to be 2.3–23.5% [9-15]. At the low end of this range, OOC prevalence may in part reflect missed ovarian tumors if pathological examination of surgical specimens was incomplete or the sample involved women who were relatively young in age. At the high end of this range, these figures may represent extensive pathologic review, biases due to sample selection, or have involved women who were relatively older in age. In order to clarify the prevalence and characteristics of OOC, we undertook a multicenter prospective cohort study of 647 women who underwent RRSO after disclosure of a positive BRCA1/2 mutation result.


Participants and data

Women with germline, disease-associated BRCA1/2 mutations were identified from 18 North American and European centers that comprise the PROSE consortium: University of Vienna, Austria; Baylor University, Beth Israel; Evanston Northwestern; Mayo Clinic; Creighton University, Omaha, NE; Dana-Farber Cancer Institute, Boston, MA; Fox Chase Cancer Center, Philadelphia, PA; Georgetown University, Washington, DC; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Netherlands Cancer Institute, Amsterdam, Netherlands; Royal Marsden Hospital, Sutton, UK; St. Mary’s Hospital, Manchester, UK; Guys Hospital, London, UK; University of Texas; Yale University, New Haven, CT; and Baylor-Charles A. Sammons Cancer Center, Dallas, TX. The BRCA1/2 mutation status of all participants was confirmed by direct mutation testing with full informed consent under protocols approved by the human subjects review boards at each institution. Women with BRCA1/2 variants of unknown functional significance were excluded.

All participants were identified via genetic testing and counseling programs for clinical and research purposes. Participants were referred by clinicians or relatives because they were perceived to be at risk for hereditary breast and/or ovarian cancer. Genetic counseling and testing was performed under clinical and/or research protocols specific to the IRB guidelines of each center. Follow-up from the time of a positive genetic test result was conducted within each center on a periodic basis. This follow-up was active but did not occur at equal intervals for all individuals in this multicenter observational study. Follow-up was random with respect to RRSO use, cancer occurrence, or death. In addition, because this was not a randomized clinical trial of RRSO, both the case and the control groups underwent a variety of cancer surveillance programs that were not controlled for in this study.

Study participants were enrolled as a prospective cohort to avoid potential biases inherent to multicenter referral studies of this type [16, 17]. Participants were defined as women with a deleterious BRCA1 or BRCA2 mutation. Women with a mutation in both BRCA1 and BRCA2, or with a variant of unknown significance, were excluded. Women were eligible if they had a genetic test disclosure date and had at least one ovary intact at the time of genetic test disclosure. For our primary analysis, we estimated the prevalence of OOC found at time of RRSO. All women in the primary analysis underwent a RRSO during the period 2001–2008 and after disclosure of their positive genetic test result. We limited the range of RRSO dates to this period to better reflect current trends in medical practice. In addition, we studied women who underwent RRSO but were not found to have any malignancy at the time of their RRSO, and we studied women who did not undergo RRSO but were diagnosed with ovarian cancer after the disclosure of their positive genetic test result (ovarian cancer cases).

Entry and follow-up of study participants at each center were undertaken without regard to surgical status. Overall research participation for potentially eligible women varied by study center from 80 to 100%, with a mean overall participation rate of 90.2%. Vital status and cancer history were obtained on all eligible participants using medical records, telephone interviews, and/or self-administered questionnaires. Reproductive and exposure history, including hormone use and smoking, were obtained by a baseline questionnaire near the time of enrollment. Follow-up data on RRSO, cancer diagnoses, and deaths were verified by review of medical records, operative notes, and/or pathology reports. Specific information collected regarding prophylactic surgeries included type of ovarian surgery and reason for surgery. Pathology data were collected at each center. Pathology reports were re-reviewed at the University of Pennsylvania. Reports were specifically examined for phrases such as “representative sections submitted” versus “entirely submitted” or “submitted in toto” to determine the extent of histologic examination.

Statistical analysis

Descriptive comparison of occult cancer and non-occult cancer controls was performed using Fisher’s Exact Test (for discrete variables) or t-test (for continuous variables). All analyses were undertaken using STATA9.1 (College Station, TX).


Among 647 women who underwent RRSO after disclosure of a positive genetic test for BRCA1/2 mutations OOC was diagnosed in 16 (2.5%). Characteristics of women in our sample are shown in Table 1. No differences in year of RRSO, pre-RRSO breast cancer status, nulliparity, number of live births, or percentage of BRCA1 versus BRCA2 mutation carriers were seen between those with or without OOC at the time of RRSO. However, compared to controls (those without OOC at RRSO), those with OOC were less likely to have ever used oral contraceptives (P = 0.046), particularly in the BRCA2 mutation carrier group (P = 0.039). In addition, BRCA1 mutation carriers with OOC were more likely to smoke compared to those without OOC (P = 0.036). Those who were found to have OOC at RRSO were born earlier than those without OOC. The mean age at RRSO among women with OOC was 51.7 years compared to 46.6 years in women without OOC (P = 0.017). When stratified by gene, these differences were accounted for by women with BRCA2 mutations, with a mean age at RRSO of women with OOC of 62.4 years compared to 48.4 years in women without OOC (P = 0.001).

Table 1
Characteristics of women with a RRSO performed 2001–2008 after disclosure of a positive BRCA1/2 test

Three of the 16 (18.8%) OOC were primary Fallopian tube cancers. Twelve of the 16 (75%) OOCs were diagnosed in women with a BRCA1 mutation. Two women with a BRCA1 mutation were diagnosed with OOC under the age of 40. Neither of these women had been diagnosed with breast cancer, both had a bilateral salpingo-oophorectomy with hysterectomy. The first woman had a C61G mutation in BRCA1, and was diagnosed with a stage 2 papillary serous carcinoma at age 35.6. The second woman, with an ex1A-2 mutation (a large genomic deletion found on MLPA with absence of exon 1a and exon 2) in BRCA1, was diagnosed with a stage 1 serous carcinoma at age 38.8. Four OOC were diagnosed in BRCA2 mutation carriers, none of these were diagnosed prior to age 40.

We detected a possible temporal trend in the diagnosis of OOC in our sample set. While the primary analysis used here included only women who had undergone RRSO in 2001–2008, the prevalence of OOC in a similarly defined prospective cohort of women undergoing RRSO prior to 2001 was lower, with 2 of 253 (0.8%) procedures done prior to 2001 resulting in OOC compared with 16 of 647 (2.5%) procedures performed from 2001 to 2008 (P = 0.119).

We also compared OOC to ovarian cancer not detected incidentally at the time of RRSO. The characteristics of the two groups were similar: there were no statistically significant differences in year of surgery, smoking, oral contraceptive use, breast cancer status, number of live births, percent with children, percentage of BRCA1 versus BRCA2 carriers, or year of birth. However, more OOC were diagnosed at earlier stage than were ovarian cancers found outside the context of RRSO (Table 2). Six of 16 (37.5%) OOC were stage I at diagnosis, compared to none of 16 non-occult ovarian cancers (P = 0.023; corrected two-sided χ2). One non-occult ovarian cancer was detected under age 40 in a BRCA1 carrier. The mean follow-up time from genetic testing to OOC or ovarian cancer diagnosis was 1.15 years. The median follow-up from diagnosis of OOC was 1.94 years, and from ovarian cancer diagnosis was 2.87 years. At the end of follow-up, 15 (94%) of women with OOC were alive. One of the 16 (6.3%) OOC cases had died of ovarian cancer. In comparison, 14 of the 16 non-occult cancer group were still alive at follow-up, while two (12.5%) had died from ovarian cancer (Fisher’s exact test P-value = 0.999).

Table 2
Women diagnosed with occult Ovarian Cancer (OOC) versus non-Occult Ovarian cancer

Pathology reports were obtained and centrally reviewed for 385 RRSO surgeries (60%). 167 of 385 (43%) RRSOs underwent concomitant hysterectomy. 245 (63.6%) of these RRSOs were performed at a participating PROSE referral center or a closely affiliated hospital, whereas 140 (36.4%) were performed at non-tertiary care centers or community hospitals. In 226 of 385 RRSOs (58.7%), ovaries and fallopian tubes were specifically stated on the pathology report to have been examined in toto. In 32 (8.3%) cases, the ovaries were examined in toto, but the fallopian tubes were not. In the remaining 127 (33.0%) RRSOs, neither ovaries nor fallopian tubes were identified as having been examined in toto. Specimens obtained at surgery at a major genetics referral center were significantly more likely to have been examined in toto compared to specimens obtained at local sites (75 vs. 30%, P < 0.001). There was no difference in the frequency of detection of occult malignancies at genetics referral centers compared with non-referral centers (3.7 vs. 4.3%, P = 0.789).

In addition to the 647 women were included in this analysis, three additional women from the PROSE cohort underwent RRSO following receipt of their genetic test results with negative pathology at the time of surgery but have subsequently developed primary peritoneal cancer. These women were excluded as controls (i.e., non-OOC) for the primary endpoint of prevalence of OOC, given the possibility that they may have had OOC at the time of their initial surgery. The inclusion of these three in the control group did not change the results (data not shown); if included as cases, the prevalence of OOC becomes 2.9%. Patient 1 underwent TAH/BSO at age 36 at a major genetics center and her ovaries were examined in toto but the fallopian tubes were not recorded as fully examined; she developed primary peritoneal cancer at age 37. Patient 2 underwent TAH/BSO at age 47 at a local center but there is no documentation that ovaries or fallopian tubes were examined in toto; she developed primary peritoneal cancer at age 52. For Patient 3, initial pathology of RRSO at age 52 was not available, and she developed primary peritoneal cancer at age 56. Mean time from RRSO to primary peritoneal cancer in these three women was 2.37 years. All three women prospectively diagnosed with primary peritoneal cancer were BRCA1 mutation carriers.


We report that OOC is detected in less than 3% of women with BRCA1/2 mutations who are undergoing RRSO, and that the tumors detected at the time of surgery are of a more favorable stage than those detected outside of prophylactic surgery.

A number of previous reports have estimated the prevalence of OOC in BRCA1/2 mutation carriers. These range from 2–3% in the larger multicenter series [10, 12, 13, 18] to 8–24% in smaller, generally single institution series with more extensive pathologic review [9, 11, 14, 19-22]. The lower estimates may in part reflect missed ovarian tumors if pathological examination of surgical specimens was incomplete or the sample involved women who were relatively young in age. Most studies with higher estimates have performed extensive pathologic review with specific attention to full sectioning of the ovaries and fallopian tubes. Such studies suggest that there may be an underestimate of OOC in the absence of complete pathologic review, particularly of the fallopian tube. Powell et al. [21] have reported a rigorous post-RRSO pathologic assessment including cytology of peritoneal washings, serial sectioning of ovaries and fallopian tubes, as well as peritoneal and omental biopsies. In 67 procedures, 7 (10.4%) occult malignancies were found in the ovaries and fallopian tubes. In second study, 6 of 62 (9.7%) women with BRCA1 or BRCA2 mutations were found to have occult neoplasia at the time of RRSO following a standard surgical and pathologic protocol that included serial sectioning of the fallopian tubes and ovaries [19]. In addition to OOC, high rates of premalignant histology have also been reported among high-risk women undergoing RRSO [23]. Therefore, the lower prevalence estimates from this study for OOC may reflect suboptimal histologic examination of the ovaries and fallopian tubes.

The data we present provide additional support for the observation seen in prior studies that there may be inadequate evaluation of surgically removed tissue in some settings. Our data show that complete histologic examination only occurred in 60% of the cases studied. When RRSO was performed at PROSE centers (i.e., specialized referral centers), the rate of complete histologic examination was significantly higher than in non-PROSE center (e.g., community hospitals). Inadequate histological evaluation may lead to failure to detect and appropriately manage occult ovarian cancer (i.e., inappropriate treatment of a primary cancer), which in turn could lead to post-RRSO peritoneal cancer and unfavorable clinical outcomes. However, in this study, only three primary peritoneal cancers were identified of which two had pathology reports available for review. In neither was there documentation of full sectioning of both the ovaries and fallopian tubes. Therefore, we do not have sufficient evidence at this time to conclude that inadequate pathologic examination increases the risk of a subsequent primary peritoneal diagnosis.

Primary peritoneal cancer has been reported in women with BRCA1/2 mutations following RRSO with an estimated frequency of 2–5%, and may occur more frequently in BRCA1 compared to BRCA2 carriers [12, 13, 24]. However, the proportion of these post-RRSO cancers that may represent relapses from an occult neoplasm remains to be determined. In studies that have examined this question, “full” pathologic examination may be associated with a very low risk of subsequent peritoneal cancer compared to those undergoing “standard” pathologic examination [19] or in those cases where salpingectomy was not performed [14, 21, 25]. The lack of intensive pathology evaluation at the time of RRSO may impact estimates of post-RRSO primary peritoneal cancer rates: if occult malignancies are missed at the time of surgery, some of these will relapse and be considered a failure of RRSO, when in fact timely diagnosis and adequate treatment could significantly improve outcome.

The importance of the fallopian tube in relationship to ovarian cancer, both in BRCA1 and BRCA2 mutation carriers and in sporadic cancers has been increasingly recognized [26, 27]. Callahan et al. [26] studied 122 BRCA1/2 mutation carriers who were undergoing RRSO at a median age of 46.5 years. They reported that 7 of these women (5.7%) had an early malignancy that originated in the fimbria or ampullary region of the fallopian tube. These data suggest that fallopian tube malignancies may represent an important site of origin of tumors detected at the time of RRSO. Three of the 16 (18.8%) OOC in our series originated in the fallopian tube.

Our findings support the current recommendations that that ovarian and fallopian tube tissue be removed as completely as possible and be examined in toto [28] (Table 3). However, the role of peritoneal washing or random peritoneal biopsies is uncertain. In Powell et al. [21], undertook intense histologic examination, and all OOC were detected on serial sectioning, none by peritoneal biopsy or washings alone. Eitan et al. [29] reported that 11% of 117 women who underwent peritoneal washings at the time of RRSO had mesothelial atypia, but none had developed peritoneal cancer at a median follow-up of 20 months. Agoff et al. [30] described two patients with abnormal peritoneal washings, but both had fallopian tube cancers on examination. At the current time, it is not clear that peritoneal washings add to complete examination of the ovaries and fallopian tubes.

Table 3
Recommendations for RRSO

The role of hysterectomy at the time of RRSO is also unclear but not routinely recommended [31]. Hysterectomy may simplify hormone replacement therapy for those women who choose to take it, but its role in further reducing ovarian/fallopian cancer risk by removing the small remnant of fallopian tube left attached to the uterine wall at the time of RRSO is unknown. Two of the three women in this series who developed primary peritoneal cancer had undergone hysterectomy at the time of their RRSO.

A number of other factors, including age, may affect the prevalence of OOC. Although not statistically significant in this study, more BRCA1 mutation carriers (3.2%) were found to have OOC compared to BRCA2 mutation carriers (1.5%), despite a later age of oophorectomy in the latter group. These data support previous findings of an increased risk of occult ovarian cancers in BRCA1 (6.4%) compared to BRCA2 (1.5%) mutation carriers [13, 19]. In our study, only two OOC were observed out of 134 (1.5%) women who underwent RRSO under age 40; compared to 14 of 513 (2.7%) 40 and older. There have been several reports suggesting that later age of RRSO significantly increases the risk of OOC. In a series of 113 high risk women, Lamb et al. [19] reported that the risk of occult neoplasia was 18.8% in BRCA1/2 mutation carriers undergoing RRSO after age 45, while others have demonstrated that older age is a significant risk factor for premalignant or malignant lesions [13, 21].

The presence of OOC in approximately 3% of BRCA1 carriers allows an estimate of lead time and a potential “window” for early identification in surveillance. Given an annual incidence of ovarian cancer around 1% in BRCA1 carriers aged 40–79 years [32, 33], and the fact that most ovarian cancers diagnosed during screening are of later stage [34], this suggests a period of about 2 years prior to symptomatic (generally stage III/IV) disease during which early diagnosis is likely to improve survival.

There are several imitations of this study. Not all pathology reports relating to RRSO were available for review. We performed a central review of available pathology reports, but not of pathology slides. Therefore, it is possible that some of specimens were examined in toto, even if they were not reported as such. However, an argument can be made that reporting should be unambiguous to the physicians taking care of women with BRCA1/2 mutations. In addition, the reason that the specimens were not processed in toto may be because the pathologists did not have all the clinical information available at the time of pathology review. At times, patients and providers have been reluctant to include BRCA1 and BRCA2 mutation status in the medical record. Given the importance of this information to the reviewing pathologist, and in light of protections afforded by the Genetic Information Non-Discrimination Act, we strongly encourage that BRCA1/2 status be made available to all care providers of women with these mutations. Finally, despite the large consortium and relatively large number of prospectively followed mutation carriers, there remain limited numbers of post-RRSO primary peritoneal cancer diagnoses in our study sample. Therefore, we are unable to link the absence of pathologic review to clinical outcomes.

In summary, OOC in BRCA1/2 mutation carriers occur. Unfortunately, many women undergoing RRSO in this prospective study did not have what is now considered standard pathologic assessment of the ovaries and fallopian tubes. Women undergoing RRSO should have salpingo-oophorectomy, and their ovaries and fallopian tubes should be examined in toto. Continued follow-up of large samples of women with BRCA1/2 mutations who have had RRSO are needed to determine whether any predictors of post-RRSO primary peritoneal cancer can be identified.


All participants provided written informed consent for participation in this study using protocols approved by the Institutional Review Boards of each contributing institution. In addition, the University of Pennsylvania Institutional Review Board approved the overall data collection and analysis protocol for the collaborative data. This study was supported by grants from the Public Health Service (R01-CA83855 and R01-CA102776 to TRR; CA74415 to SLN), the University of Pennsylvania Cancer Center (to TRR), the Cancer Genetics Network (to SMD and CI) the Dana-Farber Women’s Cancers Program (to JEG), the Department of Defense (DAMD-17-96- I-6088 to AKG; DAMD-17-94-J-4340 and DAMD-17-97-I-7112 to HTL; DAMD-17-03-1-0619 to SMD), The Utah Cancer registry (funded by Public Health Service Grant NO1-CN-6700), the Utah State Department of Health,), the National Cancer Institute (2 P30 CA51008- 15 to CI) and the Nebraska State Cancer and Smoking-Related Diseases Research Program (LB595 to HTL). DGE is supported by the NIHR Biomedical Research centre at Central Manchester Foundation Trust. OIO is Doris Duke Distinguished Clinical Scientist. None of these funding agencies had involvement in the study design; collection, analysis, or interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication.


The PROSE Consortium includes the following centers and individuals: Baylor-Charles A. Sammons Cancer Center (Joanne L. Blum, M.D. Ph.D., Becky Althaus, R.N., C.G.C., Gaby Ethington), Baylor College of Medicine (Sharon Plon, M.D., Ph.D., Claire Noll), Beth Israel Deaconess Medical Center (Nadine Tung, M.D.), City of Hope National Medical Center (Jeffery Weitzel, M.D., Veronica Lagos), Creighton University (Henry T. Lynch, M.D., Patrice Watson, Ph.D., Carrie Snyder, B.A.,), Dana Farber Cancer Institute (Judy E. Garber, M.D., M.P.H., Katherine Corso, Kathryn Stoeckert), Duke University (Joellen Schildkraut, Ph.D.), Northshore University Health System (Wendy Rubinstein, M.D., Tina Selkirk), Fox Chase Cancer Center (Mary B. Daly, M.D., Ph.D., Irene Angel), Georgetown University (Claudine Isaacs, M.D., Grace Zawistowski,), Guys and St. Thomas Foundation Trust (Gabriella Pichert, M.D., Caroline Langman, Leena Gohil) Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (Patricia A. Ganz, M.D., Joyce Seldon), Mayo Clinic College of Medicine (Fergus Couch, Ph.D.), Netherlands Cancer Institute (Marc van Beurden M.D., Ph.D., Laura van ‘t Veer, Ph.D.), Royal Marsden Hospital (Rosalind Eeles, M.D., Elizabeth Bancroft), St. Mary’s Hospital (Gareth Evans, M.D., Andrew Shenton), University of Chicago (Shelly Cummings, Olufunmilayo Olopade, M.D.), University of California, Irvine (Susan L. Neuhausen, Ph.D., Linda Steele), University of Pennsylvania (Susan Domchek, M.D., Tara Friebel, M.P.H., Timothy Rebbeck, Ph.D.), University of Texas, Southwestern (Gail Tomlinson, M.D.), University of Vienna (Christian F. Singer, Georg Pfeiler), Women’s College Hospital (Steven A. Narod, M.D.), Yale University (Ellen Matloff, M.S., Karina Brierly).


This study is conducted for the PROSE Consortium. The details of the PROSE Consortium are listed in Appendix.

Contributor Information

Susan M. Domchek, Abramson Cancer Center, The University of Pennsylvania School of Medicine, 3W Perelman Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA ; ude.nnepu.shpu@kehcmod.nasuS.

Tara M. Friebel, Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

Judy E. Garber, Dana Farber Cancer Institute, Boston, MA, USA.

Claudine Isaacs, Lombardi Cancer Center, Georgetown University, Washington, DC, USA.

Ellen Matloff, Yale University, New Haven, CT, USA.

Rosalind Eeles, The Institute of Cancer Research and the Royal Marsden NHS Trust Foundation, Sutton, Surrey, UK.

D. Gareth Evans, St. Mary’s Hospital, Manchester, UK.

Wendy Rubinstein, Northshore University Health System, Evanston, IL, USA.

Christian F. Singer, University of Vienna, Vienna, Austria.

Stephen Rubin, Abramson Cancer Center, The University of Pennsylvania School of Medicine, 3W Perelman Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.

Henry T. Lynch, Creighton University, Omaha, NE, USA.

Mary B. Daly, Fox Chase Cancer Center, Philadelphia, PA, USA.

Jeffrey Weitzel, City of Hope National Medical Center, Duarte, CA, USA.

Patricia A. Ganz, Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, CA, USA.

Gabriella Pichert, Guy’s Hospital, London, UK.

Olufunmilayo I. Olopade, University of Chicago, Chicago, IL, USA.

Gail Tomlinson, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Nadine Tung, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Joanne L. Blum, Baylor-Charles A. Sammons Cancer Center, Dallas, TX, USA.

Fergus Couch, Mayo Clinic College of Medicine, Rochester, MN, USA.

Timothy R. Rebbeck, Abramson Cancer Center, The University of Pennsylvania School of Medicine, 3W Perelman Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA, Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.


1. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case–control study. J Clin Oncol. 2005;23(30):7491–7496. [PubMed]
2. Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007;357(2):154–162. [PubMed]
3. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–87. [PMC free article] [PubMed]
4. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006;7(3):223–229. [PubMed]
5. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol. 2009;113(5):1027–1037. [PubMed]
6. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van ‘t Veer L, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804–7810. Epub 2005 Oct 7811. [PubMed]
7. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361–1367. [PubMed]
8. Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30(10):1222–1230. [PubMed]
9. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18(14):2728–2732. [PubMed]
10. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–1615. [PubMed]
11. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87(1):52–56. [PubMed]
12. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–1622. [PubMed]
13. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185–192. [PubMed]
14. Olivier RI, Lubsen-Brandsma LA, van Boven H, van Beurden M. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? Gynecol Oncol. 2005;96(2):439–443. [PubMed]
15. Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet. 2009;17(11):1381–1385. [PMC free article] [PubMed]
16. Klaren HM, van’t Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst. 2003;95(13):941–947. [PubMed]
17. Wacholder S. Bias in intervention studies that enroll patients from high-risk clinics. J Natl Cancer Inst. 2004;96(16):1204–1207. [PubMed]
18. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–1337. [PMC free article] [PubMed]
19. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006;194(6):1702–1709. [PubMed]
20. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 2001;80(2):176–180. [PubMed]
21. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J. Riskreducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23(1):127–132. [PubMed]
22. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingooophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100(1):58–64. [PubMed]
23. Hermsen BB, van Diest PJ, Berkhof J, Menko FH, Gille JJ, Piek JM, Meijer S, Winters HA, Kenemans P, Mensdorff-Pouilly SV, et al. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer. 2006;119(6):1412–1418. [PubMed]
24. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97(2):457–467. [PubMed]
25. Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97(2):476–482. [PubMed]
26. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25(25):3985–3990. [PubMed]
27. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284–5293. [PMC free article] [PubMed]
28. Karlan BY. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol Oncol. 2004;92(2):519–520. [PubMed]
29. Eitan R, Soslow R, Lin O, Kauff ND, Liu L, Barakat RR, Chi DS. The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2006;102(2):315–318. [PubMed]
30. Agoff SN, Garcia RL, Goff B, Swisher E. Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. Am J Surg Pathol. 2004;28(8):1112–1114. [PubMed]
31. Villella JA, Parmar M, Donohue K, Fahey C, Piver MS, Rodabaugh K. Role of prophylactic hysterectomy in patients at high risk for hereditary cancers. Gynecol Oncol. 2006;102(3):475–479. [PubMed]
32. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56(1):265–271. [PubMed]
33. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. [PubMed]
34. Evans GR, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dorum A, Steel M, Lalloo F, Apold J, Porteous M, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009;46(9):593–597. [PubMed]